<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577015</url>
  </required_header>
  <id_info>
    <org_study_id>184/2017</org_study_id>
    <nct_id>NCT03577015</nct_id>
  </id_info>
  <brief_title>International Prospective Registry of Disseminated Intravascular Coagulation</brief_title>
  <official_title>International Prospective Registry for the Diagnosis and Management of Disseminated Intravascular Coagulation in the Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcella Muller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universit√† degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chieti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale S. Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Poliambulanza Foundation Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester Royal Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juntendo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: to evaluate the current diagnostic and therapeutic approaches for&#xD;
      sepis-associated disseminated intravascular coagulation (DIC) in a large prospective&#xD;
      registry.&#xD;
&#xD;
      Design: prospective, multicenter, international registry. Study population: patients 18 years&#xD;
      or older with severe infection to be potentially associated with DIC will be eligible for the&#xD;
      study. The clinical visits and monitoring of the patients will follow local routine&#xD;
      practices. No specific imaging tests or laboratory evaluations will be required and patients&#xD;
      will be evaluated and treated according to local policy. All the involved centers will be&#xD;
      asked to update information on included patients at 2, 4, 6, 8, 10 and 28 days after severe&#xD;
      infection diagnosis.&#xD;
&#xD;
      Study outcomes: The primary outcome of the study is the development of DIC. Secondary&#xD;
      outcomes are thrombotic (arterial and venous) and bleeding events, overall mortality at 28&#xD;
      days.&#xD;
&#xD;
      Study sample, feasibility, and analysis plan: We plan to enroll a minimum of 1000 patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>28 Days</target_duration>
  <primary_outcome>
    <measure>disseminated intravascular coagulation</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of disseminated intravascular coagulation:&#xD;
International Society Thrombosis Hemostasis DIC score &gt;4 points (range 0-8 points) items scored: platelet count, prothrombin time, fibrinogen related marker, fibrinogen level&#xD;
Japanese Association for Acute Medicine DIC score &gt;3 points (range 0-8)points items scored: inflammatory response, platelet count, prothrombin time, fibrinogen degradation products</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disseminated intravascular coagulation</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of disseminated intravascular coagulation:&#xD;
Japanese Association for Acute Medicine DIC score &gt;3 points (range 0-8)points items scored: inflammatory response, platelet count, prothrombin time, fibrinogen degradation products</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <description>mortality rates in patient who develop or do not develop disseminated intravascular coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>venous thromboembolic events</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of symptomatic venous thromboembolic events including pulmonary embolism and deep vein thrombosis (VTE) of the upper and lower limbs, visceral VTE, and cerebral VTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial thromboembolic events</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of arterial thromboembolic events including myocardial infarction, stroke, peripheral embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and clinically-relevant non-major bleeding</measure>
    <time_frame>28 days</time_frame>
    <description>occurence of major and clinically relevant non-major bleeding</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Disseminated Intravascular Coagulation</condition>
  <arm_group>
    <arm_group_label>critically ill patients at risk for DIC</arm_group_label>
    <description>patients 18 years or older with a condition potentially associated with DIC, admitted to intensive care: severe infection/sepsis, solid tumor, hematologic malignancies, trauma, obstetric complications, acute pancreatitis</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients 18 years or older with a condition potentially associated with DIC, admitted to&#xD;
        the intensive care unit, will be eligible for the study. The maximal time-window allowed&#xD;
        between the diagnosis of the disease and inclusion in the study will be 72 hours.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admission to the intensive care unit&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
        AND one of the following conditions:&#xD;
&#xD;
          -  sepsis/severe infection&#xD;
&#xD;
          -  solid tumor&#xD;
&#xD;
          -  hematological malignancy&#xD;
&#xD;
          -  trauma&#xD;
&#xD;
          -  obstetric complications&#xD;
&#xD;
          -  acute pancreatitis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&lt;18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Boraso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OSPEDALE S. ANTONIO, Padova, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcello Di Nisio, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chieti, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jecko Tachil, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manchester Royal Infirmary, Manchester, England</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierluigi Ferretti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Poliambulanza, Brescia, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Toshiaki Iba, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>(Juntendo University, Department of Emergency and Disaster Medicine, Tokyo, Japan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandro Squizzato, MD PhD</last_name>
    <email>alessandro.squizzato@uninsurbia.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcella Muller, MD PhD</last_name>
    <phone>+31-20-5669111</phone>
    <email>m.c.muller@amc.uva.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcella Muller, MD PhD</last_name>
      <email>m.c.muller@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Juffermans, MD PhD</last_name>
      <email>n.p.juffermans@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Marcella Muller</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>disseminated intravascular coagulation</keyword>
  <keyword>sepsis</keyword>
  <keyword>trauma</keyword>
  <keyword>pancreatitis</keyword>
  <keyword>malignancy</keyword>
  <keyword>obstetric complication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disseminated Intravascular Coagulation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

